Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
|Articles|July 26, 2021
Pharmacy Times: Week of July 26 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Theresa McArdle, the senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.
- A new episode of the Pharmacy Focus podcast featuring Pamela Spicer, MS, who will be discussing new data surrounding the approval of aducanumab for Alzheimer disease.
- An article that discusses the 5 key things pharmacists need to know as insulin biosimilars come to market.
- A pharmacy quiz on treatments for diabetes.
Advertisement
Related to this article
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5